Company Information

  

Address: 1035 O'BRIEN DRIVE  
City: MENLO PARK 
State: CA 
Zip Code: 94025 
Telephone: 650-272-6269 

Description of Business

Primary SIC Code: 2836
(As filed with the SEC)  

We are a gene therapy company committed to discovering and developing novel medicines that can offer potentially life-changing therapeutic benefit to patients living with rare diseases or diseases of the eye, who currently have limited or burdensome treatment options. We are leveraging our industry-leading adeno-associated virus (AAV)-based platform to generate gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. We have also acquired certain other gene therapy product candidates through our acquisition on May 11, 2016, of Annapurna Therapeutics SAS (Annapurna), a privately-held French gene therapy company. Our core capabilities include clinical development and in-house manufacturing expertise, specifically in process development, assay development, and novel vector development and we are led by a team with significant drug development and gene therapy expertise.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-1.29NAN/E
03/2017-2.95NAN/E
09/2016-3.21NAN/E
06/2016-3.60NAN/E
03/2016-2.05NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.28Total Liab/Total Assets0.08
Net Inc/Total Assets-0.48Total Liab/Inv Cap0.08
Net Inc/Inv Cap-0.51Total Liab/Comm Equity0.05
Pretax Inc/Net Sales-78.71Interest Coverage RatioNA
Net Inc/Net Sales-78.18Curr Debt/EquityNA
Cash Flow/Net Sales-26.37LTD/EquityNA
SG&A/NetSales16.74Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables Turnover2.18Quick Ratio22.76
Inventory TurnoverNACurrent Ratio22.76
Inventory Day SalesNANet Rec/Curr Assets0.00
Net Sales/Work Cap0.01Inv/Curr AssetsNA
Net Sales/PP&E0.35  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) 0.46 0.46 0.49 0.40
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 4.06 7.99 4.78 6.15
Operating Income -12.09 -16.59 -23.39 -14.51
Interest Exp NA NA 0.00 NA
Pretax Income -11.43 -16.10 -23.17 -14.30
Other Income 0.66 0.49 0.22 0.21
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -11.43 -16.10 -22.39 -14.30

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 197.42 209.50 222.17 231.27
Receivables - Total 0.00 0.00 0.89 1.79
Inventories - Total NA NA NA NA
Total Current Assets 199.64 212.64 225.27 235.90
Net Property, Plant & Equipment 3.80 4.15 4.17 4.34
Total Assets 208.58 221.93 234.58 256.57
Liabilities        
Accounts Payable 6.35 10.01 7.93 8.84
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 8.31 11.97 9.90 10.65
Long-Term Debt NA NA NA NA
Total Liabilities 16.40 20.55 18.98 20.34
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.01 0.00 0.00 0.00
Retained Earnings -225.44 -214.01 -197.92 -175.52
Treasury Stock NA NA NA NA
Total Stockholders' Equity 192.18 201.38 215.60 236.23
Total Liabilities and Stockholders' Equity 208.58 221.93 234.58 256.57

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -11.42 -11.82 -8.34 -9.65
Net Cash Provided by Investing Activities -20.67 -138.85 -0.92 -0.36
Net Cash Provided by Financing Activities 0.16 0.19 0.20 0.00

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20120.03-1.81--
12/20130.48-5.28--
12/20140.57-25.40--
12/20152.32-47.45--
12/20161.46-113.75--
Growth Rates163.90----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/178714,30133.04




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.